Some patients with diabetes develop a serious condition known as diabetic cardiomyopathy, which is slow and cannot be directly attributed to hypertension or other cardiovascular disorders. This often ...

The EMA’s Committee for Medicinal Products for Human Use (CHMP) determined that expected clinical benefits of seladelpar include delayed development of liver fibrosis and cirrhosis, potentially ...

Some patients with diabetes develop a serious condition known as diabetic cardiomyopathy, which is slow and cannot be directly attributed to hypertension or other cardiovascular disorders.

Some patients with diabetes develop a serious condition known as diabetic cardiomyopathy, which proceeds slowly and cannot be ...

Some patients with diabetes develop a serious condition known as diabetic cardiomyopathy, which is slow and cannot be ...